ZNTL
Zentalis Pharmaceuticals, Inc.
Healthcare — Biotechnology
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. It develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types. The company also develops ZN-c3-001, a phase 1 study that evaluated azenosertib monotherapy in solid tumors; and MAMMOTH (ZN-c3-006) is a Phase 1/2 clinical trial of azenosertib in patients with PARP-inhibitor resistant ovarian cancer. It has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC. Zentalis Pharmaceuticals, Inc. was incorporated in 2014 and is based in San Diego, California.
Price History
Fundamentals
| Market Cap | $314.00M |
| P/E Ratio (TTM) | - |
| Forward P/E | -2.84 |
| EPS (TTM) | $-1.74 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | -51.93% |
| Debt/Equity | 21.16 |
| Recommendation | None |
| Analyst Target | $6.50 |
| Analysts | 8 |
| Next Earnings | May 12, 2026 |
| Indexes | - |
Technical Indicators
| RSI (14) | 65.8 |
| Beta | 1.98 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $6.95 |
| 52-Week Low | $1.15 |
| 50-Day Avg | $3.95 |
| 200-Day Avg | $2.60 |
| Avg Volume | $1.21M |
| Volume | $1.40M |
Performance Analysis
BULLISHZNTL shows predominantly bullish signals based on its fundamentals and technicals.
Recent News
Last updated: Jul 02, 2026 13:39 UTC
Back to Screener Export Report